These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39081188)

  • 1. Key insights and challeneges in noninferiority trials.
    Hong B; Lee DK
    Korean J Anesthesiol; 2024 Aug; 77(4):423-431. PubMed ID: 39081188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.
    Piaggio G; Elbourne DR; Pocock SJ; Evans SJ; Altman DG;
    JAMA; 2012 Dec; 308(24):2594-604. PubMed ID: 23268518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.
    Piaggio G; Elbourne DR; Altman DG; Pocock SJ; Evans SJ;
    JAMA; 2006 Mar; 295(10):1152-60. PubMed ID: 16522836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninferiority Trial Design: Opportunities and Challenges.
    Adidharma W; Nguyen SN; Waljee JF
    J Hand Surg Am; 2022 Nov; 47(11):1101-1106. PubMed ID: 36182582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials.
    Aberegg SK; Hersh AM; Samore MH
    J Gen Intern Med; 2018 Jan; 33(1):88-96. PubMed ID: 28875400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature.
    Eyawo O; Lee CW; Rachlis B; Mills EJ
    Trials; 2008 Dec; 9():69. PubMed ID: 19055743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equivalence and noninferiority testing in regression models and repeated-measures designs.
    Mascha EJ; Sessler DI
    Anesth Analg; 2011 Mar; 112(3):678-87. PubMed ID: 21304155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pros and Cons of Noninferiority Trials.
    Ofori S; Tornberg SV; Kilpeläinen TP; Tikkinen KAO; Guyatt GH; Witte LPW
    Eur Urol Focus; 2023 Sep; 9(5):711-714. PubMed ID: 37880063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based medicine: the design and interpretation of noninferiority clinical trials in veterinary medicine.
    Freise KJ; Lin TL; Fan TM; Recta V; Clark TP
    J Vet Intern Med; 2013; 27(6):1305-17. PubMed ID: 24128266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of reporting of noninferiority and equivalence randomized trials.
    Le Henanff A; Giraudeau B; Baron G; Ravaud P
    JAMA; 2006 Mar; 295(10):1147-51. PubMed ID: 16522835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol adherence rates in superiority and noninferiority randomized clinical trials published in high impact medical journals.
    Bamat NA; Ekhaguere OA; Zhang L; Flannery DD; Handley SC; Herrick HM; Ellenberg SS
    Clin Trials; 2020 Oct; 17(5):552-559. PubMed ID: 32666826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension.
    Liu X; Cruz Rivera S; Moher D; Calvert MJ; Denniston AK;
    Lancet Digit Health; 2020 Oct; 2(10):e537-e548. PubMed ID: 33328048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Mortality as an Endpoint in Noninferiority Trials May Lead to Ethically Problematic Conclusions.
    Hersh AM; Walter RJ; Abberegg SK
    J Gen Intern Med; 2019 Apr; 34(4):618-623. PubMed ID: 30756306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement.
    Harbin Consensus Conference Workshop Group
    Fertil Steril; 2014 Oct; 102(4):952-959.e15. PubMed ID: 25225072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension.
    Butcher NJ; Monsour A; Mew EJ; Chan AW; Moher D; Mayo-Wilson E; Terwee CB; Chee-A-Tow A; Baba A; Gavin F; Grimshaw JM; Kelly LE; Saeed L; Thabane L; Askie L; Smith M; Farid-Kapadia M; Williamson PR; Szatmari P; Tugwell P; Golub RM; Monga S; Vohra S; Marlin S; Ungar WJ; Offringa M
    JAMA; 2022 Dec; 328(22):2252-2264. PubMed ID: 36511921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodological quality of oncology noninferiority clinical trials.
    Wayant C; Ross A; Vassar M
    Crit Rev Oncol Hematol; 2020 May; 149():102938. PubMed ID: 32172223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension.
    Liu X; Cruz Rivera S; Moher D; Calvert MJ; Denniston AK;
    Nat Med; 2020 Sep; 26(9):1364-1374. PubMed ID: 32908283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular Medicine.
    Kaul S
    Can J Cardiol; 2021 Sep; 37(9):1378-1393. PubMed ID: 34118378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing noninferiority: Evaluating efficacy of a new treatment without complete data.
    Gao P; Odem-Davis K
    Pharm Stat; 2019 Oct; 18(5):546-554. PubMed ID: 30977258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals.
    Angeli F; Verdecchia P; Reboldi G
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):229-238. PubMed ID: 31650521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.